<DOC>
	<DOCNO>NCT01634958</DOCNO>
	<brief_summary>Specific immunotherapy IgE mediate sensitization grass pollen 4 concentration modify pollen extract Phleum pratense apply find optimum dose .</brief_summary>
	<brief_title>Dose Finding Study Depigoid Phleum : 4 Doses Patients With Allergic Rhinitis/Rhinoconjunctivitis +-Asthma</brief_title>
	<detailed_description>This dose find study therapeutic study . Patients receive 4-weekly interval 6x 0,5mL one 4 different concentration Depigoid Phleum . The study perform outside pollen season . Thus aim study therapeutic effect specific immunotherapy ( effect allergy specific symptom pollen season ) effect Conjunctival provocation test ( CPT ) . According EMA `` Guideline clinical development product specific immunotherapy treatment allergic disease '' provocation test accept primary outcome dose-finding study . For CPT increase dos Phleum pollen solution apply eye characteristic symptom ( eye redness , weep , itch burning , nose dripping/blockage ) assess concentration : 0=absent , 1=mild , 2=moderate , 3=severe . At score value &gt; =5/concentration test consider positive finish . It expect end study high dos necessary provoke positive CPT . Furthermore comparative evaluation safety data ( AEs ) different dosage group important parameter evaluation outcome study .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Signs Symptoms</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>appropriately sign date ICON prior study specific action IgEmediated Sensitization grass pollen Perception disease activity least 30 mm 100 mm VAS FEV1 PEFR value &gt; 80 % predict normal value Allergic rhinitis and/or rhinoconjunctivitis symptom ( least 2 year ) without intermittent asthma symptom verify : suggestive medical history AND specific IgE grass pollen CAPRAST ≥ 2 AND positive SPT ( wheal diameter ≥ 3 mm ) AND positive CPT grass pollen Patients coallergies allow enter study : asymptomatic coallergens tree weed pollen , house dust mite , cat dog , country specific allergens CAPRAST coallergen &lt; grass ( detailed specification give Birch , HDM , animal dander , country specific allergen ) All coallergens : difference CAP RAST coallergen grass ≥ 2 SPT wheal diameter coallergen &lt; grass Females nonchildbearing potential must postmenopausal least 1 year surgically sterilize Females childbearing potential must nonlactating , nonpregnant must correctly use effective method contraception study . Acute chronic infectious conjunctivitis History significant clinical manifestation allergy result sensitisation tree weed pollen perennial allergen ( e.g. , house dust mite ) Patients allow enter study : typical symptom coallergens tree weed pollen , HDM , cat dog , country specific allergens CAPRAST coallergen ≥ grass Persistent asthma , accord Global Initiative Asthma ( GINA ) Acute chronic inflammatory infectious airway disease Chronic structural disease lung ( e.g. , emphysema bronchiectasis ) Autoimmune and/or immune deficiency Any disease prohibits use adrenaline ( e.g. , hyperthyroidism ) Severe uncontrolled disease could increase risk patient participate study , include limited : cardiovascular insufficiency , severe unstable lung disease , endocrine disease , clinically significant renal hepatic disease haematological disorder . Active malignant disease previous 5 year Significant abnormal laboratory parameter alteration vital sign could increase risk study patient Abuse alcohol , drug medication within past year Severe psychiatric , psychological neurological disorder Immunotherapy grass pollen within last 5 year Systemic and/or topical treatment βblockers within 1 wk prior V2 Use medication may interfere immune system use medication might still influence immune system V2 Use tranquiliser psychoactive drug within 1 week prior V1 Use systemic corticosteroid within 3 month prior V1 Immunization vaccine within 7 day prior V2 Expected noncompliance and/or cooperation Participation another clinical study within 30 day prior V2 Prior participation study Employees investigational centre first degree relative partner investigator Planed donation germ cell , blood , organs bone marrow course study Contractually capable A positive pregnancy test V1 Jurisdictional governmentally institutionalise .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Allergic Rhinitis</keyword>
	<keyword>Hayfever</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Dose-Finding-Study</keyword>
</DOC>